Text/Golden Wrong Knife Channel
Over the years, which companies has Wang Sicong "intimidated"?
He once complained that toilet MT, chat treasure and multi-flash "is garbage, no chance".
When Zhang Dayi's Ruhan Holdings was listed, Wang Sicong did not miss the opportunity to poison his tongue, saying that he "could not cultivate new kols".
Not to mention "shot" companies such as Dianping and JD.com.
This time, Wang Sicong "tore" the target of Lianhua Qing plague capsules, shouting to the SECURITIES Regulatory Commission in the air that "I hope to strictly investigate Yiling Pharmaceutical". The words were shouted out, but his price was silenced.
On April 17, Dr. Lilac made up another knife and sent a tweet in the early morning "Don't eat Lianhua Qing plague to prevent new crown", pointing out that the drug does not have the effect of preventing new crown.
One is the Entertainment Industry Discipline Inspection Commission, a well-known big V, two fires burned at the same time to Yiling Pharmaceutical, the world's only pharmaceutical company that produces Lianhua Qing plague capsules.
In just three days, Yiling Pharmaceutical fell to a halt, and its market value plummeted by 16 billion.
You know, Lianhua Qingpeng was once a god. With this drug alone, Yiling Pharmaceutical has a revenue of 3.3 billion yuan in 9 months.
Why does Lianhua Qingpeng have so much energy? How did it become a "national miracle drug"?
Earned 3.3 billion yuan in 9 months, and even hua Qing plague three times "canonized god"
During the epidemic in Shanghai, Lianhua Qingpeng is the hard currency, and it has become the standard of anti-epidemic materials like meat and vegetables.
In fact, Lianhua Qing plague was not born for the new crown, it was born 20 years ago during the SARS period.
Behind this is inseparable from Wu Yiling, the founder of Yiling Pharmaceutical.
Wu Yiling was born in a family of traditional Chinese medicine, and in 2003, during the "SARS" period, he used his own good theory of network disease to study Lianhua Qing plague capsules.
In May 2004, Lianhua Qingpi was approved to be produced and listed, becoming the exclusive patent of Traditional Chinese Medicine of Yiling Pharmaceutical.
However, the drug description of Lianhua Qingpeng shows that this drug is mainly used for influenza.
After SARS, in H1N1, H7N9 and other influenza, Lianhua Qing plague repeatedly out of the circle.
During influenza A(H1N1), Lianhua Qingpeng was recommended as a traditional Chinese medicine treatment regimen.
This year, the sales of Lianhua Qing plague increased significantly, from 176 million grains in the previous year to 1.382 billion grains.
During the COVID-19 epidemic, Lianhua Qingfeng has become a "world net red" product.
Lianhua Qingpeng single-handedly carried half of the Zhongcheng class cold medicine and directly overtook Shuanghuanglian.
On the domestic online shopping platform, the retail price of a box of Lotus Qing Plague is only 14.8 yuan. On cross-border e-commerce ebay, the price of foreign countries has been speculated to 30 US dollars a box, and the value has soared by more than 10 times.
At the beginning of 2022, it is common for Hong Kong's Lianhua Qing plague to sell out of stock. When the overseas epidemic was serious, Lianhua Qing plague was "difficult to find a medicine", and the highest price was speculated to 385 yuan a box.
In countries that have not been approved, overseas Chinese and overseas Chinese students have not hesitated to purchase "miracle drugs" through unconventional channels at high prices.
Pooklook Fonthip, a well-known Thai actress, even if she broke the law, she also had to sell Lianhua Qingpest, and was eventually sued by Thai drug importers.
Lianhua Qing plague originated from "SARS", based on the A stream, and is famous for the new crown.
It is exported overseas and has obtained registration approvals or import licenses in more than 30 countries and regions such as Russia and Canada.
Standing behind the pharmaceutical company Yiling Pharmaceutical is even more profitable, the most direct embodiment is the performance.
In the first three quarters of 2021, Lianhua Qingpeng's revenue was 3.37 billion yuan, accounting for 41.6% of the total operating income.
After being elected as an academician of the Chinese Academy of Engineering, Wu Yiling gained fame and fortune and became a regular visitor to the rich list, known as "academician rich man".
In the 2022 Hurun Global Rich List, Wu Yiling is worth as much as 26.5 billion yuan, ranking "the richest man in Shijiazhuang".
Lianhua Qing plague into the national miracle medicine, who is the driving force behind it?
Lianhua Qing plague hardcore "backer", is the country.
Lianhua Qing plague products have been included in the diagnosis and treatment plan for colds and flu-related diseases for many times. It was not until 2020 that it was included in the fourth to ninth editions of the COVID-19 protocol.
Academician Zhong Nanshan has published a research article to clarify the role of Lianhua Qing plague in exerting antiviral activity.
Shortly thereafter, in the explanatory book of Lianhua Qing plague, a new indication for the treatment of "new crown light type and ordinary type" was added.
The national endorsement and expert effect have made Lianhua Qing plague known as a national miracle drug.
Wang Sicong and Dr. Ding Xiang "shelled" Yiling Pharmaceutical, and the point of contention was whether Lianhua Qingpeng was recommended by the WHO. That is to say, whether Yiling Pharmaceutical is suspected of false or exaggerated publicity.
Yiling Pharmaceutical publicly responded: The company has never said on any occasion that "WHO" recommends Lianhua Qingpest.
But the blogger named Xu Xiang Bit3 posted that Lian Huaqing had found himself several times to advertise, but he refused.
Weibo master "Bedtime News Editorial Department" believes that the "association" between Lianhua Qingpeng and WHO is caused by two authoritative reports, which confuses the relationship between the who-recognized efficacy of traditional Chinese medicine and the prevention and treatment of New Coronavirus.
To put it bluntly, Lianhua Qingpeng is touching the porcelain WHO.
At the same time, even the chain of interests behind Hua Qingpeng was also pulled out by netizens.
In general, if a researcher publishes an article in an academic journal, if there is a conflict of interest, either disclose it or avoid it.
However, Wu Yiling's son-in-law, Jia Zhenhua, and Academician Zhong Nanshan issued a paper together with academician Zhong Nanshan, which was not disclosed.
In this paper, in the absence of double-blind experiments, it was clear that Lianhua Qingpeng could improve the clinical cure rate.
More importantly, 10.4% of the experimental project funds came from Yiling Pharmaceutical.
At this point, the academic community stopped doing it, and the "Retraction Observation" began to crack down on counterfeiting.
Source: Zhihu @Fouzou
But one thing can prove that Yiling Pharmaceutical has invested a lot of manpower in marketing. The sales staff alone will expand from about 2,000 in 2018 to about 10,000 in 2021.
In the third quarter of 2021, the company's sales expenses were 2.8 billion yuan, accounting for more than 40% of the total operating costs, an increase of 36.48% year-on-year.
Even the explosion of the Flower Qing Plague, the driving force behind the scenes is indispensable to Yiling Pharmaceutical.
Relying on only one "miracle drug", how far can Ling Pharmaceutical go?
Whether a product has a row of noodles, there are three criteria:
First, it is extremely scarce; second, it adds value; third, it can still be collected.
Lianhua Qing plague online channel purchase limit, a person can only buy three boxes, can be called the top product during the epidemic period.
A medicine to the point of canonizing the gods, this painting style is familiar to the outside.
Zhangzhou Tablets were once known as Maotai in medicine, and were fried to 900 yuan at the highest price.
After the listing of the pharmaceutical industry, the core product is only katazai, and the company wants to stabilize the stock price, and can only create a mythical story by itself.
Tablets are not the only "miracle medicine" that has been fried into the sky. Before that, more outrageous drug hype: Angong Niuhuang Pill.
A grain of Angong Beef Yellow Pill, which was produced in the 1960s, even sold for 110,000 yuan.
This is a chinese medicine that clears the heat and relieves the heat, and in the process of being hyped, it has been given the effect of "preventing stroke". Obviously confused the concept, can't stand some people to treat it as a health care product.
When the tablets were deeply bundled with Maotai as an antidote to the liver medicine, and when the Angong Niuhuang Pill became an antique in the collection, the medicine was no longer a simple medicine, but a product of financial transactions.
But there is always a time when the story is finished, whether it is a piece of Tsai Zhen or Angong Niuhuang Pill, when the market returns to rationality, what awaits these pharmaceutical companies is a crash.
Since last year, Katazai has fallen to the altar, and the market value of 280 billion yuan has continued to fall to a halt.
Whenever there is an epidemic, there is always a drug that is put on the altar.
During the SARS period, the public grabbed vinegar, salt, and medicine, and after 2017, we still did not get rid of the "banlan root phenomenon", and even appeared "once the banlan root is drunk, the mask does not have to be worn".
Lianhua Qingpeng is not a panacea, but it has been written into the diagnosis and treatment plan of the Hebei Traditional Chinese Medicine Administration to prevent the new crown.
But how long can Yiling Pharmaceutical be prosperous?
From the past history, every explosive growth of Yiling Pharmaceutical is inseparable from the epidemic. When the epidemic can be controlled, the sales of Lianhua Qing plague will plummet.
For example, after the easing of the influenza A epidemic in 2010, Lianhua Qingpeng capsules sold only 201 million capsules, less than 1/6 of the sales volume at its peak.
That is to say, the dividend period of Lianhua Qing plague is limited.
In addition to Lianhua Qing plague, the income of other products of Yiling Pharmaceutical is not eye-catching.
More importantly, the R&D expenditure of Yiling Pharmaceutical is not high.
Source: People's Daily
In the first half of last year, The research and development expenses of Yiling Pharmaceutical were 360 million yuan, accounting for 6.1% of the revenue. This fee is lower than that of domestic non-pure Chinese medicine companies, such as BeiGene, which invested more than 9.2 billion yuan in research and development last year.
But these are far inferior to the Western medicine companies in the United States and Switzerland.
epilogue:
Wang Sicong and Dr. Ding Xiang "shelled" Lianhua Qingpest, and eventually pushed Ling Pharmaceutical to the cusp of the storm.
But Wang Sicong is not a discipline inspection commission, nor is he a food and drug administration.
Xiang Ligang, a former CCTV commentator, believes that this is a bloody dispute of interests of capital, and Lianhua Qingpeng capsules have cut off the financial road of Pfizer's "special medicine".
This argument is not unfounded, Wanda and the University of Pittsburgh Medical Center, which developed Pfizer's new crown "special drug", have a cooperation, and the United States Pfizer Company and Dr. Lilac also have a cooperative relationship.
In the prevention and control of the epidemic, who is more effective in importing special drugs and traditional Chinese medicine therapies?
It is undeniable that Chinese medicine is going to the world to fight the epidemic, and what is really needed behind this is the scientific and technological force.
When companies take the initiative to mythologize a drug, they may face a crisis of trust that can collapse at any time.
The image comes from the internet, please contact to delete the infringement
The author of this article | stars